Jan 12, 2026
New Head of West Coast business development at CBS, Allan Cortes!
Allan Cortes joins CBS as Head of West Coast business development, bringing unparalleled experience in biotech and CRO business development.
\
Pleasanton, California – 6 January 2026 – Crystal Bio Solutions (CBS) announces the appointment of Allan Cortes as Director, head of West Coast Business Development.
Mr. Cortes brings seven years of experience in biotech and CRO business development, supporting IND-stage and emerging biotechnology companies across bioanalysis, biomarkers, clinical pharmacology, and preclinical development. Most recently, he served as Director of Business Development for Bioanalysis at Celerion, where he partnered closely with sponsors to align bioanalytical strategies with clinical development timelines and built long-term relationships across the western United States.
Earlier in his career, Allan held business development roles at Amador Bioscience and BioDuro-Sundia. In these positions, he consistently expanded regional pipelines, secured multimillion-dollar opportunities, and worked cross-functionally with scientific and operational teams to support complex development programs. He also brings hands-on research experience from Avidity Biosciences, giving him a strong scientific foundation and a practical understanding of sponsor needs from discovery through early clinical development.
Strengthening Our West Coast Presence
In his new role at CBS, Allan will focus on expanding our West Coast footprint, building strategic partnerships with biotech and pharmaceutical sponsors, and working closely with our scientific and operational teams. His efforts will support the continued growth of our bioanalytical and biomarker services, as well as our Quantitative Clinical Pharmacology (QCP) capabilities.
“Allan’s background combines scientific insight with a strong track record in business development. His experience supporting early- and mid-stage biotech companies aligns well with our mission to be a trusted scientific partner across the drug development lifecycle. We are excited to have him join our team and lead our Western U.S. growth.” said Alex Chen, CEO of Crystal Bio Solutions and Crystal Pharmatech.
Supporting End-to-End Drug Development
The addition of Mr. Cortes reflects our continued investment in building a globally connected, scientifically driven organization. With integrated capabilities in CMC analytics, bioanalysis, biomarker development, and quantitative clinical pharmacology, we support programs from early discovery through clinical development and regulatory submission.
By strengthening our commercial leadership on the West Coast, we are further positioning CBS to support innovative biotech and pharma companies with high-quality data, strategic insight, and collaborative partnership.
Strategies for Antibody-Drug Conjugates Bioanalysis
Non-clinical bioanalytical studies are key in defining ADC pharmacokinetics and pharmacodynamics...
A LC-MS/MS Method for Oligonucleotide PK Bioanalysis
Our experts developed an LC-MS/MS method for oligonucleotide pharmacokinetic (PK) analysis in a Phase 1 clinical...
Sterility Assays in Drug and Device Manufacturing
Optimizing the Minimal Required Dilution (MRD) in a cLBA NAb assay we improved sensitivity...
Working on biologics?
We support drug development from R&D to IND/BLA application to commercialization
